NDAORALTABLETPriority Review
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Priority Review
Drug data last refreshed 1w ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination tablet containing lamivudine, zidovudine, and efavirenz—three antiretroviral agents used to treat HIV-1 infection. The combination works by inhibiting reverse transcriptase and reducing viral replication through complementary mechanisms. It is an oral tablet formulation designed for simplified once-daily or twice-daily dosing in HIV treatment regimens.
Pre-Launch
This pre-launch asset represents a greenfield commercial opportunity; expect rapid team scaling and market development roles as regulatory approval approaches.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Careers on this pre-launch asset center on commercial execution—market access negotiations, payer strategy, and field launch in HIV-endemic and generic-sensitive markets. This is a high-volume, price-competitive franchise requiring operational excellence and emerging-market expertise rather than novel science.
Brand ManagerField Sales Representative
Worked on LAMIVUDINE; ZIDOVUDINE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.